Bill Introduced to Mandate Pediatric Clinical Trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A measure that authorizes the FDA to mandate companies developing cancer drugs for adults to also study their products in children when there is a matching molecular target was introduced in the House and Senate earlier this week.

The RACE for Children Act—or Research to Accelerate Cures and Equity (S. 3239, H.R. 5858)—was introduced by Sens. Michael Bennet (D-Colo.) and Marco Rubio (R-Fla.), and by Reps. Michael McCaul (R-Texas), G.K. Butterfield (D-N.C.), Chris Van Hollen (D-Md.) and. Sean Duffy (R-Wis.).

The bill is intended to fix a loophole in the Pediatric Research Equity Act, which requires FDA to grant waivers to companies for cancer drugs when the drugs are developed for cancers that are not present in children, such as breast cancer, renal cell cancer and ovarian cancer.

The bill would authorize FDA to require drug developers to conduct pediatric studies under PREA when the molecular target of the claimed indications of the drugs are also relevant to childhood cancers.

Parents of children with cancer often bemoan limited availability of new treatment options.

“I was amazed to learn that although there were many exciting brain cancer drug trials that could possibly help Jacob, these drugs were not available to children,” said Nancy Goodman, the founder and executive director of Kids v. Cancer, the Washington-based advocacy group behind the bill, whose son died of a brain tumor at age 10. “Jacob received drugs that were 40 years old.”

“The laws governing childhood cancer research are misaligned with the current science of cancer drug development,” said McCaul, a sponsor of the bill. “The RACE for Children Act will modernize the law to provide for pediatric studies on the most promising and innovative treatments.”

Laura Brawley
Laura Brawley
Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.
Laura Brawley
Laura Brawley

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login